Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies

Oncologist - United States
doi 10.1634/theoncologist.2017-0152
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Alphamed Press

Related search

Regarding “Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies”

Oncologist
Cancer ResearchMedicineOncology
2017English

An Appraisal of Drug Development Timelines in the Era of Precision Oncology

Oncotarget
Oncology
2016English

Ethical Considerations for the Clinical Oncologist in an Era of Oncology Drug Shortages

Oncologist
Cancer ResearchMedicineOncology
2014English

Cn3 - Value of Adjuvant Oncology Therapies: Methodological Challenges of Modelling Cost-Effectiveness of an Adjuvant Treatment in an Era of High-Cost Oncology Treatments

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Evidence of Comparative Efficacy Should Have a Formal Role in European Drug Approvals

BMJ
2011English

2017 FDA Drug Approvals

Nature Reviews Drug Discovery
MedicineDrug DiscoveryPharmacology
2018English

Pharmacodynamic Endpoints as Clinical Trial Objectives to Answer Important Questions in Oncology Drug Development

Seminars in Oncology
OncologyHematology
2016English

Analysis of Composite Endpoints in Gene Expression Studies in Oncology

BMC Proceedings
BiochemistryMedicineGeneticsMolecular Biology
2015English

Orphan Drug Approvals in Europe: Historical Review and Trends

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy